Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Pujol

Showing results (11-20 of 95) with videos related to

Pageof 10
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|June 2, 2012
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cellsEric Badia, Aurélie Docquier, Muriel Busson, et al.
Cancer Genetics and Cytogenetics|December 2, 2004
Six novel heterozygous MLH1, MSH2, and MSH6 and one homozygous MLH1 germline mutations in hereditary nonpolyposis colorectal cancerJean-Marc Rey, Mehrdad Noruzinia, Jean-Paul Brouillet, et al.
Trends in Ecology & Evolution|February 25, 2018
Evolved Dependence in Response to CancerFrédéric Thomas, Irina Kareva, Nynke Raven, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Clinicopathologic and Prognostic Significance of Gelatinase A in Tunisian Colorectal Cancer: A Case-Control StudyDalel Ben Néjima, Yosr Ben Zarkouna, Pascal Pujol, et al.
Maturitas|May 30, 2006
Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymesLev Berstein, Tatjana Zimarina, Evgeny Imyanitov, et al.
Breast Cancer Research and Treatment|November 1, 2002
Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapyPierre-Jean Lamy, Pascal Pujol, Simon Thezenas, et al.
Cancers|February 15, 2022
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast CancersLaetitia Collet, Julien Péron, Frédérique Penault-Llorca, et al.
Nephrologie & Therapeutique|June 5, 2017
[Prospective: How will renal, prostatic and urothelial tumours be treated in 10 years?]Alain Toledano, Mayada Bourmech, Hanah Lamallem, et al.
Cell Journal|May 15, 2013
ROR2 Promoter Methylation Change in Osteoblastic Differentiation of Mesenchymal Stem CellsGorbanali Tarfiei, Mehrdad Noruzinia, Masood Soleimani, et al.
Human Mutation|March 1, 2019
Alu element insertion in the MLH1 exon 6 coding sequence as a mutation predisposing to Lynch syndromeJérôme Solassol, Marion Larrieux, Julie Leclerc, et al.
Pageof 10

Showing results (11-20 of 95) with videos related to

Sort By:
Pageof 10
The Journal of Steroid Biochemistry and Molecular Biology|June 2, 2012
Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cellsEric Badia, Aurélie Docquier, Muriel Busson, et al.
Cancer Genetics and Cytogenetics|December 2, 2004
Six novel heterozygous MLH1, MSH2, and MSH6 and one homozygous MLH1 germline mutations in hereditary nonpolyposis colorectal cancerJean-Marc Rey, Mehrdad Noruzinia, Jean-Paul Brouillet, et al.
Trends in Ecology & Evolution|February 25, 2018
Evolved Dependence in Response to CancerFrédéric Thomas, Irina Kareva, Nynke Raven, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Clinicopathologic and Prognostic Significance of Gelatinase A in Tunisian Colorectal Cancer: A Case-Control StudyDalel Ben Néjima, Yosr Ben Zarkouna, Pascal Pujol, et al.
Maturitas|May 30, 2006
Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymesLev Berstein, Tatjana Zimarina, Evgeny Imyanitov, et al.
Breast Cancer Research and Treatment|November 1, 2002
Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapyPierre-Jean Lamy, Pascal Pujol, Simon Thezenas, et al.
Cancers|February 15, 2022
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast CancersLaetitia Collet, Julien Péron, Frédérique Penault-Llorca, et al.
Nephrologie & Therapeutique|June 5, 2017
[Prospective: How will renal, prostatic and urothelial tumours be treated in 10 years?]Alain Toledano, Mayada Bourmech, Hanah Lamallem, et al.
Cell Journal|May 15, 2013
ROR2 Promoter Methylation Change in Osteoblastic Differentiation of Mesenchymal Stem CellsGorbanali Tarfiei, Mehrdad Noruzinia, Masood Soleimani, et al.
Human Mutation|March 1, 2019
Alu element insertion in the MLH1 exon 6 coding sequence as a mutation predisposing to Lynch syndromeJérôme Solassol, Marion Larrieux, Julie Leclerc, et al.
Pageof 10